Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

tion of SB-509 in diabetics with moderate to severe diabetic peripheral sensory motor neuropathy in the legs. The trial is being conducted at multiple sites, accrual has been completed and plans recently announced to expand the study and enroll additional subjects.

In the initial trial, 45 subjects have completed enrollment. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) was treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb and will be treated every 3 months. The remaining group (approximately 15 subjects) received an equal volume of placebo on the same schedule. Each subject will receive a total of two treatments (Day 0 and 90). Subjects receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

As announced on June 6, 2008, Sangamo will expand the Phase 2 study by enrolling approximately 45 additional subjects in the trial. Subjects will again be randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) will be treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group (approximately 15 subjects) will receive an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in the same pattern used in the initial part of the trial.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Specifically, investigators will assess pain using VASPI, and use scoring systems such as a modified NIS-LL and TNS to quantify neurologic exam and assess signs and symptoms of the condition.

For each subject
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
(Date:7/30/2014)... PHILADELPHIA , July 30, 2014  Packaging Coordinators, ... a definitive agreement to acquire Penn Pharmaceutical Services Limited ... Wales in the United Kingdom ... New Hope, Pennsylvania and Tokyo ... manufacturing services, including Clinical and Commercial dosage form manufacturing, ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... Nov. 10, 2010 SCOLR Pharma, Inc. (NYSE AMEX: ... and nine months ended September 30, 2010.Stephen J. Turner, SCOLR ... of the year will be to continue executing the plans ... which have both been advanced in the last quarter. ...
... Nov. 10, 2010 The Halifax Health - Betty ... celebrated the beginning of a new decade of caring ... during a ceremony held this afternoon in Daytona Beach, ... and Halifax Health will celebrate the 10th anniversary of ...
Cached Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 7Speediatrics Unit Celebrates 10th Anniversary 2Speediatrics Unit Celebrates 10th Anniversary 3
(Date:7/31/2014)... “Bivalent, Heteronomy and Natural Killer Cells?” opened ... bands ~ homeostatic CS science is the answer.” , ... new on the Bryan William Brickner Blog, ten ... cannabinoid system (CS). The line-up links to PubMed articles ... directly on homeostasis, two each on the central nervous, ...
(Date:7/31/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on nine secrets that addicts don’t ... that they can spot an addict from a mile away, ... best Drug Rehabilitation’s CEO Per Wickstrom . “However, take ...
(Date:7/31/2014)... 2014 Continuing Education Company Inc ... Clinical Issues in Primary Care Continuing Medical ... at the Wailea Beach Marriott Resort and Spa on ... been developed for today's Primary Care practitioners. In 5 ... says Barbara Lyons, VP Education. , The agenda for ...
(Date:7/30/2014)... Denver, Colorado (PRWEB) July 30, 2014 ... the skiers wearing orange vests emblazoned with “Blind Skier.” ... Colorado slopes through Foresight Ski Guides , a ... with visually impaired and blind participants (VIPs) for snow ... interested in guiding can learn more and pick up ...
(Date:7/30/2014)... DC (PRWEB) July 31, 2014 ... health care environment more responsive to an increasingly ... years of experience and scholarly expertise to the ... the health care professions: "Diversity and Cultural Competence ... 2013). Janice L. Dreachslin, PhD, a professor in ...
Breaking Medicine News(10 mins):Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Colorado Non-Profit Foresight Ski Guides Seeking Applications for Blind and Visually Impaired Skiers and Guides for Vail Ski Season 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... Chase, MD Postmenopausal women who have higher testosterone levels ... resistance and the metabolic syndrome compared to women with ... for publication in The Endocrine Society,s Journal of ... is an important step, say researchers, in understanding the ...
... ... and Total Health the all-natural herbal Nutraceutical Company together for the health of our ... ... Association and Registry (ACTHA) announced today that Total Health Enhancement Corp. ...
... ... Scrubs& Beyond shipped directly to their home or work! , ... Brentwood, MO (PRWEB) November 4, 2009 -- Medical professionals ... to their home or work! Orders will ship via SmartPost, which is a collaboration between ...
... Due to the increasing complexities of treating digestive diseases, ... enhanced abilities and experiences in specific disease areas or ... to a "Report of the Multisociety Task Force on ... the achievements of trainees based on specific defined competencies ...
... Nov. 3 Robbins & Myers, Inc. (NYSE: RBN ... Annual Industrial Conference on November 11, 2009. Representing the ... Officer, and Christopher M. Hix, Vice President and Chief Financial ... from 8:20-8:50 a.m., CT, at the Four Seasons Hotel in ...
... of Hematology (ASH) is honoring two prominent hematologists with ASH ... in the training and career development of hematologists early in ... MD, will receive their awards during the 51st ASH Annual ... receiving the Mentor Award for Basic Science, is the David ...
Cached Medicine News:Health News:Postmenopausal women with higher testosterone levels 2Health News:American Competitive Trail Horse Association Announces Total Health Enhancement Corp. as a Sponsor Member 2Health News:Smart Post Brings Scrubs & Beyond to Canadian Doorsteps 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 3Health News:The American Society of Hematology to honor inspirational hematologists with Mentor Awards 2